{'fraction_non_alphanumeric': 0.016666666666666666, 'fraction_numerical': 0.014102564102564103, 'mean_word_length': 4.8283582089552235, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Double-blind trial of oral carbuterol in bronchial asthma.

A double-blind comparison of 2 and 3 mg oral doses of carbuterol, a beta sympathomimetic drug with preferential selectivity for bronchial smooth muscle, was made with 25 and 35 mg doses of ephedrine sulfate over a six-month period in 26 patients with bronchial asthma. Spirometry was done before and three hours after administration of 3 mg of carbuterol or 35 mg of ephedrine sulfate at intervals of two weeks and one, four and six months. The data suggest a cumulative improvement in pulmonary function status with continued oral carbuterol use over the six-month period. However, the clinical effectiveness of the drug on pulmonary function was not clearly distinguishable from that of ephedrine in the present study.